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Abstract
Background: Computerized Physician Order Entry (CPOE) analgesia-sedation protocols may improve sedation
practice and patients’ outcomes. We aimed to evaluate the impact of the introduction of CPOE protocol.
Methods: This was a prospective, observational cohort study of adult patients receiving mechanical ventilation,
requiring intravenous infusion of analgesics and/or sedatives, and expected to stay in the intensive care unit (ICU)
≥24 h. As a quality improvement project, the study had three phases: phase 1, no protocol, July 1st to September
30th, 2010; phase 2, post implementation of CPOE protocol, October 1st to December 31st, 2010; and phase 3,
revised (age, kidney and liver function adjusted) CPOE protocol, August 1st to October 31st, 2011. Multivariate
analyses were performed to determine the independent predictors of mortality.
Results: Two hundred seventy nine patients were included (no protocol = 91, CPOE protocol = 97, revised CPOE
protocol = 91). Implementation of CPOE protocol was associated with increase of the average daily dose of fentanyl
(3720 ± 3286 vs. 2647 ± 2212 mcg/day; p = 0.009) and decrease of hospital length of stay (40 ± 37 vs. 63 ± 85 days,
p = 0.02). The revised CPOE protocol was associated with, compared to the CPOE protocol, a decrease of the average
daily dose of fentanyl (2208 ± 2115 vs. 3720 ± 3286 mcg/day, p = 0.0002) and lorazepam (0 ± 0 vs. 0.06 ± 0.26 mg/day,
p = 0.04), sedation-related complications during ICU stay (3.3 % vs. 29.9 %, p <0.0001), and ICU mortality (18 % vs. 39 %,
p = 0.001). The impact of the revised CPOE protocol was more evident on patients aged >70 years or with severe
kidney or liver impairment. Both the original CPOE protocol and the revised CPOE protocol were not independent
predictors of ICU (adjusted odds ratio [aOR] = 1.85, confidence interval [CI] = 0.90–3.78; p = 0.09; aOR = 0.70,
CI = 0.32–1.53, p = 0.37; respectively) or hospital mortality (aOR = 1.12, CI = 0.57–2.21, p = 0.74; aOR = 0.80,
CI = 0.40–1.59, p = 0.52; respectively).
Conclusions: The implementation of a CPOE analgesia-sedation protocol was not associated with improved
sedation practices or patients’ outcome but with unpredicted increases of an analgesic dose. However, the
revised CPOE protocol (age, kidney and liver function adjusted) was associated with improved sedation practices. This
study highlights the importance of carefully evaluating the impact of changes in practice to detect unanticipated
outcomes.
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Background
Sedation is a major component of the management of
critically ill and mechanically ventilated patients. Several
studies have suggested that sedation is often overused in
patients in the intensive care unit (ICU) [1, 2]. Specific
strategies to reduce excessive sedations have been rec-
ommended including the daily interruption of sedation
[3] and implementation of protocol that facilitate the ti-
tration of sedatives to a sedation score [4, 5]. However,
the use of these strategies in clinical practice has been
inconsistent.
Clinical practice guidelines (CPGs) [6] were developed
to assist practitioners in the establishment and implemen-
tation of sedation protocols appropriate to their patient
population. The implementation of recommendations
from these CPGs may involve changes in sedation prac-
tice. Evaluating the impact of such changes is an import-
ant quality assurance activity. It is essential to measure
outcomes, and to determine whether the objectives of the
practice change have been achieved.
The use of sedation protocols based on CPGs to guide
analgesia and sedation therapy in the ICU is recom-
mended [7] and has been shown to improve patient out-
comes including mechanical ventilation duration, ICU
and hospital length of stay (LOS), and ICU and hospital
mortality [8, 9]. However, in an Australian ICU, a ran-
domized trial provided no evidence of a substantial
improvement of outcomes with the use of protocol-
directed sedation compared with usual local manage-
ment [10]. Moreover, the implementation of a sedation
protocol may have been associated with adverse out-
comes not previously reported in the literature.
Additionally, prolonged use of continuous infusions of
analgesics and sedatives results in accumulation of these
drugs as well as their active metabolites leading to over-
sedation, greater hemodynamic instability, and pro-
longed mechanical ventilation and ICU stay [11]. The
risk of accumulation of analgesics and sedatives is
greater in patients with slow metabolism or low drug
clearance such as elderly and patients with renal or hep-
atic dysfunction.
A computerized physician order entry (CPOE)-based
analgesia-sedation protocol, derived from the CPGs [6],
was developed for implementation in our ICU. As a con-
tinuous quality improvement project, the objective of
this study was to evaluate whether the implementation




The study was conducted in the 21-bed medical-surgical
and trauma ICU in an 800-bed tertiary teaching hospital
in Riyadh, Saudi Arabia. The ICU, which admits more
than 1000 patients per year, is run as a closed unit 24 h
a day, 7 days a week by in-house, full-time, critical care
board-certified intensivists.
Design
This was a prospective longitudinal, observational, co-
hort study that was conducted in three phases, each of
3-months duration. Phase 1 was prior to the implemen-
tation of a CPOE-based analgesia-sedation protocol (July
1st to September 30, 2010) (no protocol group). Phase 2
was immediately after implementation (October 1st to
December 31, 2010) (CPOE protocol group). Finally,
phase 3 was after revision of the protocol (August 1st to
October 31, 2011) (revised CPOE protocol group), fol-
lowing a plan-do-study-act cycle. The ICU Quality
Improvement Committee approved the protocol and the
data collection process as it was considered as quality
improvement project. Approval of the Research Com-
mittee of the hospital was not required as the protocol
was introduced as a clinical tool and the study as a mon-
itoring procedure to this tool. In addition, all arms of
the study, the no protocol, the CPOE protocol and the
revised CPOE protocol, were considered acceptable
clinical practices.
Patients
All consecutive patients receiving mechanical ventila-
tion, who were judged by their treating team to re-
quire intravenous infusion of analgesics and/or
sedatives, aged ≥18 years and expected to stay in the
ICU for ≥24 h, were included in the study. Patients
were excluded if they were being administered epi-
dural analgesia, did not require sedation in the first
24 h, readmitted to the ICU within the same
hospitalization, pregnant, post cardiac arrest, clinically
brain dead, or with Do-Not-Resuscitate status.
Study protocols
Prior to implementation of the CPOE protocol, the
patients received analgesics and/or sedatives as per
individual physician preference using CPOE and the
following units: mcg/hour for fentanyl, mg/hour for
morphine, propofol and midazolam, and mcg/kg/hour
for dexmedetomidine.
The CPOE protocol group received analgesics and/or
sedatives using a CPOE-based goal-directed, nurse-driven
protocol that was derived from the available CPGs [6]. It
incorporated the following analgesics and sedatives:
fentanyl, dexmedetomidine (both, mcg/kg/hour), mor-
phine, propofol, and midazolam (all three, mg/hour). The
key components of this sedation protocol are: establish-
ment of a sedation goal, use of pain and sedation scoring
systems, and daily interruption of sedation when appropri-
ate. Nurses used validated scales to assess, every 4 h, pain
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(Numeric Rating Scale [NRS]) [12–14] and sedation
(Sedation-Agitation Scale [SAS]) [15], and titrated and ta-
pered infusions to achieve and maintain the target pain
(NRS ≤2) and sedation (SAS: 4 to 1 as required) scores.
An increment or decrement of 10 % of the ongoing infu-
sions was used to titrate or taper sedatives and/or analge-
sics until discontinuation of all infusions. Fentanyl was
preferred for patients with unstable hemodynamic, renal
or hepatic failure; propofol or dexmedetomidine were pre-
ferred if sedation was planned for ≤3 days and benzodiaze-
pines if sedation was planned for >3 days.
As part of the quality improvement project, and fol-
lowing a plan-do-study-act cycle, we noticed, an unex-
pected, increase in the average daily dose of fentanyl
after implementing the CPOE protocol. Consequently,
the CPOE protocol was revised. After this revision, the
patients (revised CPOE protocol group) received analge-
sics and/or sedatives using a goal-directed, nurse-driven;
age, kidney and liver function adjusted sedation proto-
col; and the following units: mcg/kg/hour for fentanyl
and propofol; mg/hour for morphine and midazolam;
and mcg/kg/hour for dexmedetomidine; with similar key
components of the protocol group. Patients were divided
into three categories: age <60 years, and normal kidney
and liver function (risk 1); age = 60 to 70 years, or mod-
erate kidney or liver function impairment (risk 2); and
age >70 years, or severe kidney or liver function impair-
ment (risk 3) (Table 1). The upper limits of analgesics
and sedatives doses were determined according to the
risk category, being lowest in risk 3 category and lower
in risk 2 category than in risk 1 category. “Modification
of Diet in Renal Disease” (MDRD) was used as surrogate
for kidney function, and “Model for End-Stage Liver
Disease” (MELD) was used as surrogate for liver function.
Normal kidney function was defined as MDRD ˃90, mod-
erate kidney function impairment as MDRD= 30–90, and
severe kidney function impairment as MDRD ˂30.
Whereas, normal liver function was defined as MELD ˂8,
moderate liver function impairment as MELD= 8–14, and
severe liver function impairment as MELD ˃14.
Data collection
For the first seven ICU days, experienced dedicated
nurses [4] collected the following data: total daily doses
of analgesics and sedatives; NRS, SAS and Glasgow
Coma Scale (GCS) scores every 4 h; and sedation-related
complications during ICU stay. The nurse who collected
data for an individual patient was not involved in that
patient’s care. The following data, prospectively collected
by a full-time data collector, were extracted from the
ICU electronic database: patients’ demographics (age,
gender, and body mass index [BMI]); Acute Physiology
And Chronic Health Evaluation (APACHE) II [16]; organ
failure indicators (GCS score, PaO2/FiO2, creatinine, bili-
rubin, platelets count, International Normalized Ratio
[INR], and the presence of shock defined as hypotension
[systolic blood pressure <90 mm Hg requiring vasopres-
sors not including dopamine at doses of <5 mcg/kg/
min]); admission categories (medical, surgical, trauma,
respiratory, cardiovascular, and neurological); and severe
chronic illnesses (chronic respiratory disease, chronic
cardiovascular disease, chronic renal disease, chronic
liver disease, and chronic immunosuppression).
Outcome measurements
The primary outcomes were: mechanical ventilation dur-
ation, ICU and hospital LOS, and ICU and hospital mor-
tality. Secondary outcomes were: average daily doses of
analgesics and sedatives; average NRS, SAS and GCS
scores; and sedation-related complications during ICU
stay (agitation [SAS = 5]; very agitated [SAS = 6]; danger-
ous agitation [SAS = 7]; self-removal of endotracheal/
tracheotomy tube, nasogastric tube, arterial/central/per-
ipheral line, drains and urinary catheter; and CT-brain
for mental status evaluation).
Statistical analysis
Baseline characteristics were presented as number and
percent for categorical variables, or mean and standard
deviation for continuous ones. Comparison between the
three groups (no protocol, CPOE protocol and the
revised CPOE protocol) was carried out using the Chi-
square test for categorical variables, whereas the inde-
pendent student’s t-test was used for continuous variables.
Stepwise logistic regression analyses were carried out to
identify predictors of outcomes adjusting for chronic car-
diovascular disease, chronic liver failure, APACHE II,
PaO2/FiO2, and GCS. These predictors considered were
those, which were found to be statistically significant, or
those, which are known to be clinically significant. Odds
Ratio (OR) and 95 % Confidence Intervals (CI) were re-
ported, along with the p-value. All analyses were carried
Table 1 Definition of risk 1, risk 2 and risk 3 categories
Variable Risk 1 category Risk 2 category Risk 3 category
Age, years <60, and 60 to 70, or >70, or
Kidney function Normal (MDRD ˃90), and Moderate impairment (MDRD = 30–90), or Sever impairment (MDRD ˂30), or
Liver function Normal (MELD ˂8) Moderate impairment (MELD = 8–14) Sever impairment (MELD ˃14)
MDRD Modification of Diet in Renal Disease (surrogate for kidney function), MELD Model for End-Stage Liver Disease (surrogate for liver function)
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out using the Statistical Analyses Software, version 9.1.




Two hundred seventy nine patients were included in the
study (no protocol = 91, CPOE protocol = 97, revised
CPOE protocol = 91). Table 2 shows patients’ baseline
characteristics of which most variables were not signifi-
cantly different between the three groups. However,
PaO2/FiO2 was higher in the no protocol group
compared to the CPOE protocol group (238 ± 120 vs.
202 ± 103, p = 0.03), GCS was higher in the CPOE proto-
col group compared to the revised CPOE protocol group
(11 ± 5 vs. 9 ± 4, p = 0.02), and chronic cardiovascular
disease was more frequent in the no protocol and the
CPOE protocol groups compared to the revised CPOE
protocol group (18 % vs. 6 %, p = 0.01; 26 % vs. 6 %,
p = 0.0001; respectively).
Outcomes
The results of crude analyses of primary and secondary
outcomes are shown in Table 3.
Table 2 Baseline characteristics
Variable No protocol CPOE protocol Revised CPOE protocol P-value P-value P-value
(n = 91) (n = 97) (n = 91) 1 vs. 2 2 vs. 3 1 vs. 3
Age, years (mean ± SD) 50 ± 22 51 ± 20 49 ± 22 0.67 0.5 0.82
Male gender, n (%) 59 (65) 59 (61) 60 (66) 0.57 0.47 0.88
Vasopressors, n (%) 52 (59) 62 (64) 55 (60) 0.5 0.62 0.85
Sepsis, n (%) 32 (35) 37 (38) 30 (33) 0.67 0.46 0.75
BMI (mean ± SD) 29 ± 9 29 ± 7 29 ± 16 0.94 0.92 0.97
APACHE II (mean ± SD) 24 ± 9 25 ± 10 23 ± 8 0.45 0.13 0.47
Admission category
Medical, n (%) 19 (21) 26 (27) 21 (23) 0.9641 0.54 0.57
Surgical, n (%) 29 (32) 30 (31) 25 (28)
Trauma, n (%) 5 (6) 5 (5) 9 (10)
Respiratory, n (%) 5 (6) 5 (5) 8 (9)
Cardiovascular, n (%) 13 (14) 12 (13) 15 (17)
Neurological, n (%) 20 (22) 19 (20) 13 (14)
Organ failure indicators
PaO2/FiO2 (mean ± SD) 238 ± 120 202 ± 103 211 ± 106 0.03 0.56 0.12
GCS (mean ± SD) 10 ± 4 11 ± 5 9 ± 4 0.45 0.02 0.11
Creatinine (mean ± SD) 120 ± 93 151 ± 159 120 ± 122 0.097 0.13 0.99
Bilirubin (mean ± SD) 64 ± 93 54 ± 66 51 ± 85 0.37 0.85 0.34
Platelets (mean ± SD) 200 ± 155 199 ± 160 215 ± 155 0.99 0.49 0.5
INR (mean ± SD) 1.6 ± 0.7 1.8 ± 1.4 1.7 ± 0.99 0.19 0.54 0.42
Severe chronic illnesses
Chronic respiratory disease, n (%) 8 (9) 8 (8) 8 (9) 0.89 0.89 1
Chronic cardiovascular disease, n (%) 16 (18) 25 (26) 5 (6) 0.17 0.0001 0.01
Chronic renal disease, n (%) 10 (11) 7 (7) 9 (10) 0.37 0.51 0.81
Chronic liver disease, n (%) 10 (11) 13 (13) 5 (6) 0.61 0.07 0.18
Chronic immunosuppression, n (%) 10 (11) 16 (17) 13 (14) 0.27 0.68 0.50
Risk Groups
Risk 1 patients, n (%) 24 (26) 24 (25) 35 (38) 0.96 0.12 0.21
Risk 2 patients, n (%) 18 (20) 19 (20) 16 (18)
Risk 3 patients, n (%) 49 (54) 54 (56) 40 (44)
1: No protocol; 2: CPOE Protocol; 3: Revised CPOE Protocol; APACHE Acute Physiology and Chronic Health Evaluation, BMI body mass index, GCS Glasgow Coma
Scale, INR International Normalized Ratio; Risk 1: age ˂60 years, normal kidney function (MDRD ˃90), normal liver function (MELD ˂8); Risk 2: age = 60–70 years,
moderate kidney function impairment (MDRD = 30–90), moderate liver function impairment (MELD = 8–14); Risk 3: age ˃70 years, severe kidney function
impairment (MDRD ˂30), severe liver function impairment (MELD ˃14)
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Outcomes stratified by risk
Table 4 summarizes primary and secondary outcomes of
patients with risk 1, risk 2 and risk 3 for the three study
groups.
Predictors of ICU and hospital mortality
Multivariate logistic regression analyses showed that the
CPOE protocol and the revised CPOE protocol were not
independently associated with ICU (adjusted odds ratio
[aOR] = 1.85, 95 % confidence interval [CI] = 0.90–3.78, p
= 0.09; aOR = 0.70, CI = 0.32–1.53, p = 0.37; respectively) or
hospital (aOR = 1.12, CI = 0.57–2.21, p = 0.74; aOR = 0.80,
CI = 0.40–1.59, p = 0.52; respectively) mortality (Table 5).
Predictors of ICU and hospital mortality stratified by risk
The results of multivariate logistic regression analyses
for the three risk groups are shown in Table 6. In
patients with risk 1 and risk 2, the CPOE protocol and
the revised CPOE protocol were not independently asso-
ciated with ICU or hospital mortality. In patients with
risk 3, the CPOE protocol was independently associated
with increased ICU mortality (aOR = 2.64, CI = 1.03–
6.56, p = 0.04), but was not associated with hospital mor-
tality (aOR = 1.43, CI = 0.59–3.46, p = 0.43). The revised
CPOE protocol was not associated with ICU (aOR =
0.68, CI = 0.24–1.88, p = 0.45) or hospital (aOR = 1.11,
CI = 0.44–2.79, p = 0.82) mortality.
Discussion
Our study demonstrates that the implementation of a
CPOE-based goal-directed, nurse-driven, analgesia-
sedation protocol was not associated with improved pa-
tients’ outcomes. We observed a significant increase in
the average daily dose of fentanyl that was
Table 3 Primary and secondary outcomes
Variable No protocol CPOE protocol Revised CPOE protocol P-value P-value P-value
(Mean ± SD) (n = 91) (n = 97) (n = 91) 1 vs. 2 2 vs. 3 1 vs. 3
Primary outcomes
Mechanical ventilation duration, mean ± SD, days 10 ± 9 12 ± 11 10 ± 8 0.21 0.2 0.98
ICU LOS, mean ± SD, days 12 ± 10 13 ± 12 13 ± 11 0.78 0.91 0.69
Hospital LOS, mean ± SD, days 63 ± 85 40 ± 37 46 ± 42 0.02 0.32 0.09
ICU mortality, n (%) 24 (26) 38 (39) 16 (18) 0.06 0.001 0.15
Hospital mortality, n (%) 36 (40) 43 (44) 29 (32) 0.51 0.08 0.28
Secondary outcomes
Average daily doses of analgesics and sedatives
Fentanyl, mcg/day 2647 ± 2212 3720 ± 3286 2208 ± 2115 0.009 0.0002 0.17
Morphine, mg/day 0.71 ± 4.88 0.36 ± 2.11 0.45 ± 2.18 0.54 0.79 0.64
Dexmedetomidine, mcg/day 47.6 ± 113.7 48.3 ± 153.5 40.6 ± 124.1 0.97 0.71 0.69
Midazolam, mg/day 84 ± 107 78 ± 101 68 ± 96 0.71 0.48 0.3
Propofol, mg/day 271 ± 650 274 ± 833 509 ± 961 0.97 0.07 0.052
Lorazepam, mg/day 0.09 ± 0.32 0.06 ± 0.26 0 ± 0 0.47 0.04 0.01
Haloperidol, mg/day 0.27 ± 0.87 0.42 ± 1.77 0.23 ± 0.85 0.45 0.34 0.72
Paralytics, mg/day 28 ± 61 20 ± 60 21 ± 49 0.34 0.84 0.41
Average NRS, SAS and GCS scores
NRS score, mean ± SD 0.24 ± 0.5 0.16 ± 0.36 1.02 ± 0.73 0.20 <0.0001 <0.0001
SAS score, mean ± SD 2.5 ± 1.1 2.3 ± 1.1 2.5 ± 1.2 0.47 0.25 0.66
GCS score, mean ± SD 6.8 ± 3.2 6.6 ± 3.2 6.9 ± 2.9 0.84 0.36 0.47
Sedation-related complications during ICU stay
Agitated (SAS = 5), n (%) 37 (40.7) 29 (29.9) 3 (3.3) 0.12 <0.0001 <0.0001
Very agitated (SAS = 6), n (%) 10 (11) 6 (6.2) 3 (3.3) 0.24 0.5 0.04
Dangerous agitation (SAS = 7), n (%) 4 (4.4) 1 (1) 2 (2.2) 0.2 0.61 0.68
NGT self-removal, n (%) 2 (2.2) 2 (2.1) 0 (0) 1 0.5 0.5
ETT self-removal, n (%) 2 (2.2) 0 (0) 0 (0) 0.23 - 0.5
Brain CT scans for mental status assessment, n (%) 1 (1.1) 0 (0) 0 (0) 0.48 - 1
1: No protocol; 2: CPOE Protocol; 3: Revised CPOE Protocol; CT computed tomography, ETT endotracheal tube, GCS Glasgow Coma Scale, ICU intensive care unit,
LOS length of stay, NGT nasogastric tube, NRS Numeric Rating Scale, SAS Sedation-Agitation Scale, SD standard deviation
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Table 4 Primary and secondary outcomes stratified by risks
Variable No protocol CPOE protocol Revised CPOE protocol P-Value P-Value P-Value
(n = 91) (n = 97) (n = 91) 1 vs. 2 2 vs. 3 1 vs. 3
Risk 1 patients: age ˂60 years, normal kidney function (MDRD ˃90), normal liver function (MELD ˂8)
Primary outcomes
Mechanical ventilation duration, mean ± SD, days 5.9 ± 6.4 12.2 ± 12.2 10.5 ± 9.4 0.21 0.55 0.40
ICU LOS, mean ± SD, days 10.3 ± 7.4 13.3 ± 15.2 12.2 ± 11.5 0.39 0.75 0.44
Hospital LOS, mean ± SD, days 78.4 ± 95.4 52.3 ± 53.5 50.8 ± 56.6 0.25 0.92 0.22
ICU mortality, n (%) 3 (13) 3 (13) 4 (11) 1 1 1
Hospital mortality, n (%) 5 (21) 5 (21) 4 (11) 1 0.46 0.46
Secondary outcomes
Average daily doses of analgesics and sedatives
Fentanyl, mean ± SD, mcg/day 3694 ± 2315 3711 ± 2879 2613 ± 2257 0.98 0.11 0.08
Morphine, mg/day 2.2 ± 9.3 0.93 ± 3.8 1.09 ± 3.4 0.54 0.87 0.58
Dexmedetomidine, mean ± SD mcg/day 52 ± 112 125 ± 269 42 ± 93 0.23 0.16 0.72
Midazolam, mean ± SD, mg/day 158 ± 148 111 ± 132 98 ± 113 0.26 0.67 0.08
Propofol, mean ± SD, mg/day 564 ± 947 812 ± 1517 643 ± 1063 0.50 0.62 0.77
Lorazepam, mg/day 0.17 ± 0.52 0.10 ± 0.31 0 ± 0 0.58 - -
Haloperidol, mg/day 0.17 ± 0.49 0.90 ± 2.8 0.37 ± 1.19 0.22 0.39 0.37
Paralytics, mg/day 50.3 ± 85.4 47.3 ± 104.2 30.5 ± 59.7 0.91 0.48 0.30
Average NRS, SAS and GCS scores
NRS score, mean ± SD 0.28 ± 0.54 0.22 ± 0.4 1.01 ± 0.86 0.63 <0.0001 0.0002
SAS Score, mean ± SD 2.2 ± 1.1 2.5 ± 1.1 2.5 ± 1.3 0.47 0.96 0.46
GCS score, mean ± SD 6.4 ± 3.4 6.9 ± 3.4 7 ± 3.3 0.58 0.95 0.50
Sedation-related complications during ICU stay
Agitated (SAS = 5), n (%) 7 (29.2) 9 (37.5) 0 (0) 0.54 <0.0001 0.001
Very agitated (SAS = 6), n (%) 3 (12.5) 2 (8.3) 1 (2.9) 1.00 0.56 0.29
Dangerous agitation (SAS = 7), n (%) 2 (8.3) 1 (4.2) 0 (0) 100 0.41 0.16
NGT self-removal, n (%) 1 (4.2) 0 (0) 0 (0) 1.00 - 0.41
ETT self-removal, n (%) 0 (0) 0 (0) 0 (0) - - -
Brain CT scans for mental status assessment, n (%) 0 (0) 0 (0) 0 (0) - - -
Risk 2 patients: age = 60–70 years, moderate kidney function impairment (MDRD = 30–90), moderate liver function impairment (MELD = 8–14)
Primary outcomes
Mechanical ventilation duration, mean ± SD, days 9.6 ± 8.2 12.7 ± 13.8 8.4 ± 6.0 0.40 0.22 0.64
ICU LOS, mean ± SD, days 11.3 ± 8.6 13 ± 12.1 11.4 ± 12.3 0.64 0.72 0.97
Hospital LOS, mean ± SD, days 70.8 ± 95.3 45.3 ± 27.6 53.3 ± 42.2 0.29 0.51 0.49
ICU mortality, n (%) 2 (11) 2 (11) 2 (13) 1 1 1
Hospital mortality, n (%) 3 (17) 2 (11) 3 (19) 0.66 0.64 0.87
Secondary outcomes
Average daily doses of analgesics and sedatives
Fentanyl, mean ± SD mcg/day 2336 ± 1979 4153 ± 3967 2759 ± 2455 0.09 0.23 0.58
Morphine, mg/day 0.19 ± 0.59 0.02 ± 0.07 0.15 ± 0.42 0.23 0.22 0.83
Dexmedetomidine, mean ± SD mcg/day 47 ± 67 54 ± 119 60 ± 214 0.82 0.92 0.81
Midazolam, mean ± SD mg/day 59 ± 75 91 ± 88 98 ± 122 0.24 0.85 0.26
Propofol, mean ± SD mg/day 201 ± 326 118 ± 285 759 ± 1425 0.42 0.1 0.14
Lorazepam, mg/day 0.75 ± 0.23 0.02 ± 0.07 0 ± 0 0.36 - -
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Table 4 Primary and secondary outcomes stratified by risks (Continued)
Haloperidol, mg/day 0.92 ± 1.58 0.26 ± 0.61 0.14 ± 0.56 0.11 0.55 0.06
Paralytics, mg/day 6.0 ± 14.4 5.4 ± 14.6 25.9 ± 57.7 0.90 0.19 0.20
Average NRS, SAS and GCS scores
NRS score, mean ± SD 0.44 ± 0.80 0.23 ± 0.53 0.93 ± 0.69 0.35 0.002 0.06
SAS score, mean ± SD 3.1 ± 0.9 2.8 ± 1.0 2.3 ± 1.2 0.42 0.24 0.055
GCS score, mean ± SD 7.7 ± 2.2 8.2 ± 4.0 6.4 ± 3 0.64 0.13 0.14
Sedation-related complications during ICU stay
Agitated (SAS = 5), n (%) 10 (55.6) 9 (47.4) 0 (0) 0.62 0.001 0.0004
Very agitated (SAS = 6), n (%) 3 (16.7) 1 (5.3) 0 (0) 0.34 1.00 0.23
Dangerous agitation (SAS = 7), n (%) 1 (5.6) 0 (0) 0 (0) 0.49 - 1.00
NGT self-removal, n (%) 1 (5.6) 2 (10.5) 0 (0) 1.00 0.49 1.00
ETT self-removal, n (%) 0 (0) 0 (0) 0 (0) - - -
Brain CT scans for mental status assessment, n (%) 0 (0) 0 (0) 0 (0) - - -
Risk 3 patients: age ˃70 years, severe kidney function impairment (MDRD ˂30), severe liver function impairment (MELD ˃14)
Primary outcomes
Mechanical ventilation duration, mean ± SD, days 11.3 ± 10.0 11.8 ± 9.0 10.9 ± 7.1 0.81 0.61 0.82
ICU LOS, mean ± SD, days 13.2 ± 11.6 12 ± 9.9 13.6 ± 9.5 0.56 0.42 0.86
Hospital LOS, mean ± SD, days 52.5 ± 75.4 33 ± 29.8 39.1 ± 22.7 0.10 0.28 0.25
ICU mortality, n (%) 19 (39) 33 (61) 10 (25) 0.02 0.0005 0.17
Hospital mortality, n (%) 28 (57) 36 (67) 22 (55) 0.32 0.25 0.84
Secondary outcomes
Average daily doses of analgesics and sedatives
Fentanyl, mean ± SD mcg/day 2232 ± 2108 3571 ± 3245 1633 ± 1719 0.01 0.0003 0.15
Morphine, mg/day 0.14 ± 0.82 0.23 ± 1.3 0 ± 0 0.68 0.19 0.24
Dexmedetomidine, mean ± SD mcg/day 46 ± 130 12 ± 51 32 ± 102 0.10 0.28 0.57
Midazolam, mean ± SD mg/day 55 ± 71 58 ± 84 30 ± 42 0.85 0.03 0.04
Propofol, mean ± SD mg/day 148 ± 508 90 ± 240 293 ± 523 0.48 0.03 0.19
Lorazepam, mg/day 0.05 ± 0.18 0.05 ± 0.28 0 ± 0 0.99 - -
Haloperidol, mg/day 0.08 ± 0.43 0.27 ± 1.41 0.13 ± 0.51 0.34 0.51 0.58
Paralytics, mg/day 25.8 ± 54.8 12.8 ± 35.8 12.0 ± 32.6 0.17 0.91 0.15
Average NRS, SAS and GCS scores
NRS score, mean ± SD 0.15 ± 0.27 0.11 ± 0.25 1.07 ± 0.61 0.46 <0.0001 <0.0001
SAS score, mean ± SD 2.3 ± 1.1 2.1 ± 1.0 2.6 ± 1.0 0.31 0.02 0.18
GCS score, mean ± SD 6.5 ± 3.2 5.9 ± 2.9 7.4 ± 2.6 0.32 0.01 0.17
Sedation-related complications during ICU stay
Agitated (SAS = 5), n (%) 20 (40.8) 11 (20.4) 3 (7.5) 0.02 0.08 0.0004
Very agitated (SAS = 6), n (%) 4 (8.2) 3 (5.6) 2 (5) 0.71 1.00 0.69
Dangerous agitation (SAS = 7), n (%) 1 (2) 0 (0) 2 (5) 0.48 0.18 0.59
NGT self-removal, n (%) 0 (0) 0 (0) 0 (0) - - -
ETT self-removal, n (%) 2 (4.1) 0 (0) 0 (0) 0.22 - 0.50
Brain CT scans for mental status assessment, n (%) 1 (2) 0 (0) 0 (0) 0.48 - 1.00
1: No protocol; 2: CPOE Protocol; 3: Revised CPOE Protocol; CT computed tomography, ETT endotracheal tube, GCS Glasgow Coma Scale, ICU intensive care unit,
LOS length of stay, MDRD Modification of Diet in Renal Disease (surrogate for kidney function), MELD Model for End-Stage Liver Disease (surrogate for liver function),
NGT nasogastric tube, NRS Numeric Rating Scale, SAS Sedation-Agitation Scale
Haddad et al. BMC Anesthesiology  (2015) 15:177 Page 7 of 10
predominantly in patients with risk 3 (Tables 3, 4). Fur-
thermore, the CPOE protocol was associated with a sig-
nificant increase in the ICU mortality in patients with
risk 3 (Table 4). However, revision of the protocol by
adjusting for age, kidney and liver function resulted in
elimination of the increase in the average daily dose of
fentanyl, and loss of the association with mortality in pa-
tients with risk 3. The impact of the revised CPOE
protocol was more evident on patients with risk 3. Com-
pared to no protocol and to CPOE protocol, the revised
CPOE protocol was associated with a significant increase
in the NRS score, however, within acceptable level; and a
significant decrease in the sedation-related complica-
tions during ICU stay (agitated, SAS = 5).
Optimizing sedation practice, using ICU protocols for
sedation, is recognized as quality indicator and is be-
lieved to be important in improving patient outcomes
[17]. However, the implementation of a sedation proto-
col is a dynamic process that requires reassessment.
This assessment allows periodic modification of the
protocol to ensure that the projects’ objectives are be-
ing met. Our study demonstrates the importance of
monitoring and measuring the impact of implementa-
tion of an analgesia-sedation protocol that derived from
CPGs, since paradoxical effects resulted from its imple-
mentation. In our institution, the implementation of a
CPOE-based goal-directed, nurse-driven, analgesia-
sedation protocol was associated with a significant in-
crease in the ICU mortality in elderly patients
(>70 years) and in patients with severe kidney or liver
function impairments, and a significant increase in the
average daily dose of fentanyl. The significant increase
of the average daily dose of fentanyl in the CPOE
protocol group compared to the no protocol group is
possibly due the change of units used for dosing. Prior
to implementation of the protocol; commonly and re-
gardless of age, weight, gender, or renal or liver
function; the ordered dose of fentanyl ranged from 50
to 200 mcg/hour. In the CPOE protocol, the fentanyl
dose was 0.5 – 5 mcg/kg/hour. This resulted in an
hourly dose that may have reached up to 500 mcg in a
100 kg patient and 700 mcg in a 140 kg patient. The
trend towards higher ICU mortality in the protocol
group may be potentially due to the significantly high
dose of fentanyl, and differences in baseline character-
istics (the CPOE protocol group had higher mean cre-
atinine and significantly lower mean of PaO2/FiO2
ratio. The increase in the daily dose of propofol that
was associated with the implementation of the revised
CPOE protocol was possibly due to the decrease of the
average daily dose of fentanyl that was used not only as
an analgesic but also as a sedative.
Although, CPOE has been recommended [18] to re-
duce human and medication errors during health care
delivery, and therefore improve patient safety, studies
demonstrate conflicting results of its impact on morbid-
ity and mortality [19, 20]. Han et al., documented an in-
crease in mortality after implementation of CPOE in a
tertiary care children’s hospital [19], however, Del
Beccaro et al., reported that implementation of CPOE
was not associated with increased mortality in tertiary
care pediatric ICU [20]. Our study is the first to evaluate
the impact of a CPOE-based analgesia-sedation protocol
on doses of analgesics and sedatives, and on patients’
outcome. Unexpectedly, the initial implementation of
CPOE-based analgesia-sedation protocol was not associ-
ated with improved outcome, however, with increased
doses of analgesics, and with increased ICU mortality in
patients with high-risk (risk 3).
This study has a number of strengths including the
prospective nature of data collection by a full-time ded-
icated data collector and dedicated nurses; the col-
lection of pharmacologic, physiologic and clinical
endpoints; and the inclusion of all consecutive eligible
patients during the study periods. The study also had
several limitations. First, the study was observational
and of pre-post design, therefore, the influence of other
confounders cannot be excluded. Second, the study was
conducted in a single center. Third, the use of MELD
and MDRD as surrogates for kidney and liver dysfunc-
tion, respectively, is controversial. Forth, delirium, an
important outcome of sedation, was not assessed dur-
ing the study. Finally, the compliance with the proto-
cols was not measured, and the use of protocol was not
forced-function as drugs that are used in the protocols
could be prescribed through the search function out-
side the protocols.
Conclusions
The implementation of a CPOE-based analgesia-
sedation protocol was not associated with improved
Table 5 Predictors of ICU and hospital mortality (multivariate
logistic regression analysis)
Variable Adjusted odds ratio (95 % CI) P-value
ICU mortality
CPOE protocol 1.85 (0.90–3.78) 0.09
Revised CPOE protocol 0.70 (0.32–1.53) 0.37
Chronic liver disease 5.92 (2.30–15.23) 0.0002
APACHE II 1.12 (1.07–1.16) <0.0001
Hospital mortality
CPOE protocol 1.12 (0.57–2.21) 0.74
Revised CPOE protocol 0.80 (0.40–1.59) 0.52
Chronic liver disease 4.68 (1.70–12.89) 0.003
APACHE II 1.14 (1.09–1.18) <0.0001
APACHE Acute Physiology and Chronic Health Evaluation, CPOE computerized
physician order entry, ICU intensive care unit
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patients’ outcome. However, its initial implementation
was associated with increased ICU mortality in the eld-
erly and in patients with severe renal or hepatic failure.
Once revised and with the incorporation of age, kidney
and liver function, the protocol was associated with im-
proved sedation practices and patients’ outcomes. Our
experience demonstrates that the implementation of
sedation protocols should be regularly monitored to de-
tect inadvertent consequences. When designing a sed-
ation protocol, we suggest that it includes adjustment
for patient’s age, and kidney and liver function. Integrat-
ing such sedation protocols may decrease the amount of
analgesic and/or sedative agents and improve patient
outcome.
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